期刊文献+

1例危重化脓性脑膜炎患者治疗的药学实践 被引量:1

Pharmaceutical Practice in the Treatment of a Patient with Severe Purulent Meningitis
下载PDF
导出
摘要 临床药师参与1例危重化脓性脑膜炎患者的药物治疗,与临床医师共同制定个体化抗感染方案,使患者的感染得到有效控制。临床药师积极参与药学实践,优化药物治疗方案,有利于提高临床抗感染治疗水平。 The clinical pharmacist participated in treating a patient with severe purulent meningitis,and made an individualized anti-infection program cooperating with the clinicians.The individualized pharmaceutical practice performed by the clinical pharmacist effectively controlled the infection.The active participation in pharmaceutical practice and therapeutic program optimization by clinical pharmacists can improve the therapeutic level.
作者 张艳利 王海涛 张莉 邱财荣 Zhang Yanli;Wang Haitao;Zhang Li;Qiu Cairong(Department of Pharmacy,The No.987 Hospital of the PLA Joint Logistics Support Force,Shaanxi Baoji 721004,China;The Second Affiliated Hospital of Xi'an Jiaotong University)
出处 《中国药师》 CAS 2019年第12期2245-2248,共4页 China Pharmacist
关键词 临床药师 化脓性脑膜炎 药学实践 Clinical pharmacist Purulent meningitis Pharmaceutical practice
  • 相关文献

参考文献6

二级参考文献31

  • 1朱曼,郭代红,石莉,宁静,裴保香.2000-2004年我院4种抗癫痫药物血药浓度监测结果分析[J].药物流行病学杂志,2005,14(4):223-225. 被引量:3
  • 2中华人民共和国卫生部药政局.抗菌药物临床应用指导原则[S].1993.
  • 3Karam CM, McKinnon PS, Neuhauser MM, et al. Outcomeassessment of minimizing vancomycin monitoring and dosingadjustments[J]. Pharmacotherapy, 1999, 19(3): 257-266.
  • 4Rybak MJ. The pharmacokinetic and pharmacodynamic propertiesof vancomycin[J]. Clin Infect Dis, 2006, 42(Suppl 1): S35-S39.
  • 5Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeuticmonitoring of vancomycin in adult patients: a consensus reviewof the American Society of Health-System Pharmacists, theInfectious Diseases Society of America, and the Society ofInfectious Diseases Pharmacists[J]. Am J Health Syst Pharm,2009, 66(1): 82-98.
  • 6Lee P, DiPersio D, Jerome RN, et al. Approaching and analyzing a large literature on vancomycin monitoring andpharmacokinetics[J]. J Med Libr Assoc, 2007, 95(4): 374-380.
  • 7Hermsen ED, Hanson M, Sankaranarayanan J, et al. Clinicaloutcomes and nephrotoxicity associated with vancomycin troughconcentrations during treatment of deep-seated infections[J].Expert Opin Drug Saf, 2010, 9(1): 9-14.
  • 8Fu JJ, Ye XH, Chen C, et al.The Efficacy and Safety of Li- nezolid and glycopeptides in the treatment of staphylococ- cus aureus infections [J]. PLoS One, 2013,8 (3) : e58 240.
  • 9Pletz MW, Burkhardt O, Welte T.Nosocomial methicillin- resistant staphylococcus aureus (Mrsa) pneumonia. Line- zolid or vancomycin? Comparison of pharmacology and clinical efficacy [J].Eur J Med Res, 2010,30 (15) : 507.
  • 10Dryden MS.Linezolid pharmacokinetics and pharmacody- namics in Clinical treatment [J].JAntimicrob Chemother, 2011,66(Suppl 4) : iv7.

共引文献440

同被引文献11

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部